Introduction {#s1}
============

According to the DSM 5 (2013), Autism Spectrum Disorder (ASD) is characterized by functional deficits in three areas: mental development, social interaction, and behavior ([@B1]). In a multicenter epidemiological study done in 2012, involving nine countries, the median estimate of prevalence of ASD was 62/10.000 inhabitants ([@B2]). In clinical practice, the term ASD comprises a broad group of syndromes, diseases, and disorders ([@B3], [@B4]), that can affect cognitive development, motor skills, social interaction, communication, and behavior (frequently including auto and hetero-aggressiveness) ([@B5]--[@B15]). Often, this set of functional deficits results in incapacitation, lack of independence and severe distress for patients, families, and caregivers. For a recent review on this topic, refer to ([@B16]).

It is believed that ASD has multifactorial causes, generally associated with chromosomal or epigenetic changes in many different genes, which are often associated with neuronal function ([@B17]--[@B24]). Currently, there are no drugs or psychotherapeutic approaches capable of comprehensively improving life quality, social skills, and cognitive development of the most severe ASD patients ([@B25]--[@B31]). Currently available drugs may mitigate some specific symptoms, but generally speaking, they do so with a narrow range of effectiveness, and are often associated with important side effects ([@B32], [@B33]). Antipsychotic, antidepressant, or anxiolytic drugs, for example, may soothe autistic patients who display self-aggressive behavior ([@B33]--[@B36]). Antiepileptic drugs may be effective for seizure control and may even improve sleep quality and behavioral aspects ([@B37]). However, these drugs are known to cause major side effects ([@B38]--[@B46]). Moreover, none of these drus has been shown to significantly improve the lack of social interaction and communication skills that characterize and impose great impact on the lives of patients with ASD and their families.

Recent observational studies and trials reporting the use of pure CBD or CBD-enriched cannabis extracts for the treatment of syndromes characterized by refractory epilepsy and regressive autism suggest therapeutic potential of cannabinoids for autistic symptoms ([@B47]--[@B60]). These studies, which include extracts with a CBD/THC ratio of up to 20/1, showed that, even in children and adolescents, the side effects of these extracts are infrequent and less damaging than those reported for drugs traditionally used either for ASD, ADHD, sleep disorders, or epilepsy.

Changes in the expression of peripheral cannabinoid receptors were verified in autistic patients, suggesting possible deficiencies in the production and regulation of endogenous cannabinoids in ASD ([@B61]). This hypothesis has been recently confirmed specifically for anandamide, a major endocannabinoid, which is reduced in ASD patients ([@B62]). The understanding of the possible mechanisms involving the endocannabinoid system in the etiology of ASD has been derived from basic research in animal models. Special attention has been given to the neuronal hyperexcitability hypothesis and its possible relationship with the endocannabinoid system, which may also explain the higher incidence of epilepsy among ASD patients ([@B63]--[@B68]). Significant epileptform EEG activity has been recorded even in the central nervous system of non-epileptic autistic children ([@B69]), which is consistent with the "intense world hypothesis," that relates autistic symptoms to excessive neuronal activity and connectivity ([@B70]). Together, these findings strongly support the need for testing *Cannabis sativa* extracts (CEs) and isolated phytocannabinoids as pharmacological approaches to control severe symptoms in both epileptic and non-epileptic ASD patients ([@B68]). Furthermore, CBD has been shown to have anxiolytic ([@B71]--[@B75]) and antipsychotic effects ([@B76]--[@B79]) in humans. It is plausible to assume that such effects are, at least in part, mediated by CBD-induced accumulation of the endocannabinoid anandamide ([@B80]). Although the mechanisms underlying CBD-induced antiepileptic effects are not entirely clear, anandamide modulation is likely to play an important role ([@B68]). In this context, it is interesting to note that anandamide accumulation, caused by inhibitors of its metabolic degradation, leads to reduction of social interaction deficits in the valproate-treated animal model of autism ([@B81]).

Here we report an observational study analyzing the effects of the compassionate use of *Cannabis sativa* extract (CE) containing a 75/1 CBD/THC ratio, which was given to a group of 18 ASD patients. The participant group includes 11 patients with no history of epilepsy, two previously diagnosed with epilepsy but seizure-free for over a year, and 5 currently diagnosed with epilepsy who had seizures during the month preceding treatment with CE. Treatment results were assessed by means of monthly questionnaires and clinical evaluation. The results after 6--9 months of treatment were extremely promising for both epileptic and non-epileptic patients. For the latter, observed improvements were much more comprehensive with fewer adverse effects than it would have been expected from currently available therapies. These preliminary results indicate, therefore, the urgent need for more extensive and detailed clinical studies to further validate the use of ECs and cannabinoids for the treatment of severe ASD symptoms.

Materials and Methods {#s2}
=====================

Participants
------------

The initial cohort included 18 ASD patients (ICD 10 = F84), aged 06--17 years (average 10), including five (28%) females and 13 (72%) males. Treatment with CE was spontaneously pursued by the patient\'s parents, who obtained legal authorization from the National Sanitary Surveillance Agency of Brazil (ANVISA) for the compassionate use of CE with all clinical assistance and treatment follow-up supervised by one of the authors of this article (P. F). Out of the 18 patients who had initiated treatment with standardized CE, three abandoned the treatment in the first month. Among the 15 patients who remained in the study, 05 had a diagnosis of epilepsy and had had seizures in the month preceding CE treatment, while the remaining 10 had never been diagnosed with epilepsy or had not had any clinical seizures for more than 12 months before treatment with CE. Among the five epileptic patients, one was diagnosed with Dravet\'s syndrome, two had epilepsy associated with cerebral palsy, and two had refractory epilepsy of undetermined etiology. Non-epileptic cases were randomly numbered 1--10, while epileptic cases were randomly numbered from 11 to 15. Demographic data are detailed in [Table 1](#T1){ref-type="table"}, while the individual patient\'s symptom profiles are detailed in [Table 2](#T2){ref-type="table"}.

###### 

Cohort description and individual dosage[^\*^](#TN1){ref-type="table-fn"} of phytocannabinoids prescribed.

  **Case \#**                          **Age (years)**   **Weight (kg)**   **CBD (mg/kg/day)**   **THC (mg/kg/day)**   **CBD (mg/day)**   **THC (mg/day)**
  ------------------------------------ ----------------- ----------------- --------------------- --------------------- ------------------ ------------------
  01[^f^](#TN2){ref-type="table-fn"}   07                25.0              4.00                  0.05                  100.00             1.33
  02[^m^](#TN3){ref-type="table-fn"}   12                45.0              3.89                  0.05                  175.00             2.33
  03[^m^](#TN3){ref-type="table-fn"}   09                33.0              3.79                  0.05                  125.00             1.67
  04[^m^](#TN3){ref-type="table-fn"}   12                80.0              4.38                  0.06                  350.00             4.67
  05[^f^](#TN2){ref-type="table-fn"}   11                34.0              5.88                  0.08                  200.00             2.67
  06[^m^](#TN3){ref-type="table-fn"}   10                26.0              3.85                  0.05                  100.00             1.33
  07[^m^](#TN3){ref-type="table-fn"}   09                32.0              3.91                  0.05                  125.00             1.67
  08[^f^](#TN2){ref-type="table-fn"}   08                35.0              4.29                  0.06                  150.00             2.00
  09[^m^](#TN3){ref-type="table-fn"}   14                49.0              4.08                  0.05                  200.00             2.67
  10[^m^](#TN3){ref-type="table-fn"}   12                32.0              4.69                  0.06                  150.00             2.00
  11[^m^](#TN3){ref-type="table-fn"}   18                89.5              3.35                  0.04                  300.00             4.00
  12[^m^](#TN3){ref-type="table-fn"}   07                15.5              6.45                  0.09                  100.00             1.33
  13[^f^](#TN2){ref-type="table-fn"}   15                46.0              5.43                  0.07                  250.00             3.33
  14[^m^](#TN3){ref-type="table-fn"}   09                25.0              6.00                  0.08                  150.00             2.00
  15[^m^](#TN3){ref-type="table-fn"}   11                35.0              4.29                  0.06                  150.00             2.00
  Average                              10.9              40.1              4.6                   0.06                  175.0              2.33
  STD                                  3.06              20.18             0.94                  0.01                  74.40              0.99

*The administration schedule was of two daily doses, one in the morning and one in the evening*.

*Female patients*.

*Male patients*.

###### 

Caretakers\' perception of improvement in each symptom category.

  **Case \#**                              **Months of CE treatment[^\#^](#TN7){ref-type="table-fn"}**   **Perception of improvement of symptoms (%)[^\*^](#TN6){ref-type="table-fn"}**                                  
  ---------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------- ----- ---- ---- ---- ---- ---- -----
  01[^f^](#TN4){ref-type="table-fn"}       09                                                            15                                                                               15    \-   10   15   15   50   \-
  02[^m^](#TN5){ref-type="table-fn"}       06                                                            40                                                                               10    20   30   60   40   40   \-
  03[^m^](#TN5){ref-type="table-fn"}       09                                                            40                                                                               30    40   20   40   30   50   \-
  04[^m^](#TN5){ref-type="table-fn"}       15                                                            30                                                                               20    20   10   40   30   30   \-
  05[^f^](#TN4){ref-type="table-fn"}       27                                                            50                                                                               25    35   20   25   35   40   \-
  06[^m^](#TN5){ref-type="table-fn"}       09                                                            30                                                                               00    \-   00   00   20   \-   \-
  07[^m^](#TN5){ref-type="table-fn"}       09                                                            15                                                                               15    15   15   15   15   50   \-
  08[^f^](#TN4){ref-type="table-fn"}       09                                                            20                                                                               20    \-   10   60   20   60   \-
  09[^m^](#TN5){ref-type="table-fn"}       09                                                            00                                                                               −10   20   00   00   20   \-   \-
  10[^m^](#TN5){ref-type="table-fn"}       09                                                            30                                                                               25    20   10   30   15   \-   \-
  11[^m^](#TN5){ref-type="table-fn"}       09                                                            85                                                                               85    10   25   30   50   60   100
  12[^m^](#TN5){ref-type="table-fn"}       09                                                            50                                                                               00    55   00   40   10   25   ≥50
  13[^f^](#TN4){ref-type="table-fn"}       09                                                            20                                                                               20    00   00   00   00   20   ≥50
  14[^m^](#TN5){ref-type="table-fn"}       39                                                            35                                                                               40    20   15   25   30   85   ≥50
  15[^m^](#TN5){ref-type="table-fn"}       09                                                            00                                                                               00    00   00   00   00   10   100
  *n*[^\#\#^](#TN8){ref-type="table-fn"}                                                                 15                                                                               15    12   15   15   15   12   05
  Median                                                                                                 30                                                                               20    20   10   25   20   40   NA

*ADHD, Attention Deficit/Hyperactivity Disorder; BD, Behavioral Disorders; MD, Motor Deficits; AD, Autonomy Deficits; CSID, Communication and Social Interaction Deficits; CD, Cognitive Deficits; SD, Sleep Disorders; SZ, Seizures*.

*female patients*.

male patients.

*Lack of improvement is computed as 00% and worsening of symptoms are recorded as negative values*.

Total time of CE use, including before the onset of standardized CE.

Number of patients presenting each symptom. A dash (-) indicate lack of the symptom before treatment onset. NA, Not applicable.

*Scores for seizures are: 00, for lack of improvement, \<50%, for reduction of \<50% in the occurrence of SZ, ≥50%, for reduction of more than 50% in the occurrence of SZ; or 100% for cases of complete cessation of SZ*.

Treatment
---------

In August 2016, all patients started receiving standardized CE, with the same composition and origin, manufactured by CBDRx® (Colorado, USA). The standardized CE contained a proportion of \~75/1 CBD/THC and was administered orally in capsules containing 25 or 50 mg of CBD and \~0.34 or 0.68 mg of THC, respectively (according to data provided by the manufacturer).

From the 18 patients who started standardized CE treatment, 15 had never used any CE previously, while three had already used CEs for periods ranging from 5 to 24 months. The standardized CE doses were established individually by a titration process within a dose range based on CBD doses previously reported for use of CBD-enriched CEs for treatment of refractory epilepsy associated with regressive autism ([@B53], [@B54], [@B57], [@B58], [@B60]). Thus, the average initial dose of CBD was \~2.90 mg/kg/day, varying according to individual case severity at the beginning of treatment (minimum: 2.30 mg/kg/day and maximum: 3.60 mg/kg/day). Dosage adjustment was done intensively during the first 30 days and more sparsely over the following 150 days. The average dose of CBD administered from then until the end of the study was 4.55 mg/kg/day, with a minimum of 3.75 and a maximum of 6.45 mg/kg/day ([Table 1](#T1){ref-type="table"}). The average dose of THC in the same period was 0.06 mg/kg/day, with a minimum of 0.05 and a maximum of 0.09 mg/kg/day. Individual maintenance doses used by patients after the adjustment period are shown in [Table 1](#T1){ref-type="table"}, which does not include patients who abandoned the standardized CE treatment during the first month. The administration schedule was of two daily doses, one in the morning and one in the evening.

Cannabinoid Extract Acquisition
-------------------------------

By means of a non-commercial collaboration between the *Brazilian Association of Medicinal Cannabis Patients* (also known as AMAME) and the manufacturer CBDRx®, the standardized CE was donated by the company CBDRx LLC at no charge to the patients.

Data Acquisition
----------------

The patient\'s parents and/or caregiver received a standardized form by e-mail ([Supplementary Material](#SM1){ref-type="supplementary-material"}), which should be answered once before the beginning of the study (baseline), and monthly throughout the duration of the CE treatment. In these forms the parents/caregivers were asked to estimate the severity of each of the eight symptom categories evaluated (see [Supplementary Material](#SM1){ref-type="supplementary-material"}). They should inform a score between 0 and 100, in which 0 means the lowest level of performance (or the maximum level of deficit and impairment associated to the symptom), and 100 means maximum performance (or complete absence of deficit and impairment associated to that symptom). The data presented here correspond to the difference observed between baseline results and results reported in the final month of treatment.

To ensure that the parents/caregiver properly understood the meaning of each category and that they were using the numeric scores in a consistent way throughout the study, the forms also contained two accessory questions (see [Supplementary Material](#SM1){ref-type="supplementary-material"}). In the first of these accessory questions the caregivers were asked to freely describe, in their own words, what changes they had observed since the last month. In the second accessory question parents/caregivers were asked to inform the degree of change in a 5-level Likert-like scale, for each group of symptoms, in relation to the previous month. The three different responses allowed the detection of inconsistencies. Every month the patient\'s physician (P. F.) checked the numeric evaluation for consistency, and whenever an inconsistency was observed the physician would contact the parent/caregiver, either in person or by phone, and ask them to consider adjusting the response.

Evaluation of the Results
-------------------------

Patients were followed by means of periodic clinical evaluations made by the physician in charge. A monthly questionnaire was used to record treatment effects based on the answers given by the parents. Monthly standardized forms were filled out and contained questions covering the following symptom categories (see [Supplementary Material](#SM1){ref-type="supplementary-material"} for a detailed description of each category): Attention Deficit/Hyperactivity Disorder (ADHD);Behavioral Disorders (BD);Motor Deficits (MD);Autonomy Deficits (AD);Communication and Social Interaction Deficits (CSID);Cognitive Deficits (CD);Sleep Disorders (SD);Seizures (SZ).

Parents answered the initial questionnaires in August 2016 to assess the presence or absence of these symptoms before the onset of CE treatment. In the monthly questionnaires that followed for the next 9 months, until April 2017, the perceived percentage change for each symptom category was assessed. Clinical assessments and monthly records also included information regarding side effects and changes, maintenance, reduction, or withdrawal of neuropsychiatric drugs that were already in use ([Table 2](#T2){ref-type="table"}).

The descriptive statistics in [Figures 1A,B](#F1){ref-type="fig"} were plotted in MATLAB 2017a using the default settings of the *boxplot* function from the "Statistics and Machine Learning Toolbox."

![Improvement of symptoms observed in the patients that underwent CE treatment for at least 6 months. Data was collected from the caretakers\' monthly follow-up questionnaires. **(A)** Pooled data from all 15 patients in the following categories: attention deficit/hyperactivity disorder (ADHD, *n* = 15); behavioral disorders (BD, *n* = 15); motor deficits (MD, *n* = 12); autonomy deficits (AD, *n* = 15); communication and social interaction deficits (CSID, *n* = 15); cognitive deficits (CD, *n* = 15); sleep disorders (SD, *n* = 12); convulsive seizures (SZ, *n* = 5). **(B)** Subset including only the 10 non-epileptic patients that underwent CE treatment for at least 6 months. Attention deficit/hyperactivity disorder (ADHD, *n* = 10); behavioral disorders (BD, *n* = 10); motor deficits (MD, *n* = 7); autonomy deficits (AD, *n* = 10); communication and social interaction deficits (CSID, *n* = 10); cognitive deficits (CD, *n* = 10); sleep disorders (SD, *n* = 7). Red lines denote medians, blue boxes the interquartile range, black whiskers the minimum and maximum values. Note that all categories present improvements that range from modest to robust, in spite of a very short period of treatment with CE.](fneur-10-01145-g0001){#F1}

Results {#s3}
=======

General Results
---------------

Three patients (one female and two males, or 17% out of the cohort of 18 patients) chose to suspend treatment before the end of the first month due to the occurrence of adverse effects. In two of these patients a worsening of symptoms may have been due to the concomitant and unsupervised attempt to remove or reduce the dosage of antipsychotics. The third patient may have suffered adverse effects of the interaction of the prescribed cannabinoids with two other psychiatric medications that were being used simultaneously. For the remaining 15 patients that adhered to the standardized CE treatment, the consolidated results recorded during the final month of treatment are presented in [Table 2](#T2){ref-type="table"} and graphically depicted in [Figure 1A](#F1){ref-type="fig"}. Results for all non-epileptic patients are presented in [Figure 1B](#F1){ref-type="fig"}. No differences were observed between genders, and for that reason results for both genders are shown together.

Overall, mostly positive outcomes were reported for the 15 patients that adhered to the standardized CE treatment (one case for 6 months and 14 cases for 9 months), especially regarding improvements in sleep disorders, seizures, and behavioral crisis. Also, signs of improvement were reported for motor development, communication and social interaction, and cognitive performance ([Table 2](#T2){ref-type="table"}). We highlight that 14 out of these 15 patients (93%) showed improvements equal to or above 30% in at least one symptom category. Most patients that adhered to the treatment had improvements in more than one symptom category: seven patients (47%) had improvements equal to or above 30% in four or more symptom categories; two patients (13%) presented improvements equal to or above 30% in two symptom categories, and five patients (33%) presented improvements equal to or above 30% in one symptom category. Only one patient, referred to as Case 9, who was receiving multiple neuropsychiatric medications throughout the study, presented overall maintenance or worsening of symptoms.

Results Grouped by Symptom Categories
-------------------------------------

Clinical assessment and records of patients\' evolution, which were filled in monthly by the patients\' guardians/caretakers, targeted the main symptom categories associated with autism. Possible side effects of CE administration and modifications in the dosage of other neuropsychiatric drugs that were prescribed were also evaluated and are presented in [Table 3](#T3){ref-type="table"}. From the 15 patients who adhered to the treatment with standardized EC, 15 had symptoms of ADHD; 15 of BD; 12 of MD; 15 of AD; 15 of CSID; 15 of CD; 12 of SD; and 5 of SZ. Also, as shown in [Table 3](#T3){ref-type="table"}, 10 of these patients were also concomitantly taking other prescribed neuropsychiatric medications (OM).

###### 

Neuropsychiatric drugs taken by each patient during the study.

  **Case \#**                           **OM in use before CE treatment**                                                 **OM in use after CE treatment**                **Summary of changes in OM**            **CE side effects**
  ------------------------------------- --------------------------------------------------------------------------------- ----------------------------------------------- --------------------------------------- --------------------------------------------------------------------
  01[^f^](#TN10){ref-type="table-fn"}   None                                                                              None                                            No OM                                   None
  02[^m^](#TN11){ref-type="table-fn"}   Risperidone + Melatonin                                                           None                                            Complete withdrawal                     None
  03[^m^](#TN11){ref-type="table-fn"}   None (used oxcarbazepine before the study)                                        None                                            No OM                                   None
  04[^m^](#TN11){ref-type="table-fn"}   None                                                                              None                                            No OM                                   Nocturia and polyuria
  05[^f^](#TN10){ref-type="table-fn"}   None (used several OM before the study)                                           None                                            Complete withdrawal                     None
  06[^m^](#TN11){ref-type="table-fn"}   None                                                                              None                                            No OM                                   Hyperaemia, sleepiness, and transient increase in core temperature
  07[^m^](#TN11){ref-type="table-fn"}   Promethazine + Risperidone                                                        Risperidone                                     Partial withdrawal                      Transient sleepiness
  08[^f^](#TN10){ref-type="table-fn"}   Melatonin + Risperidone                                                           Risperidone                                     Partial withdrawal + dosage reduction   Slight increase in appetite
  09[^m^](#TN11){ref-type="table-fn"}   Oxcarbazepine + Risperidone + Levomepromazine                                     Oxcarbazepine + Risperidone + Levomepromazine   None                                    None
  10[^m^](#TN11){ref-type="table-fn"}   None                                                                              None                                            No OM                                   None
  11[^m^](#TN11){ref-type="table-fn"}   Carbamazepine + Risperidone                                                       Risperidone                                     Partial withdrawal + dosage reduction   Transient diarrhea at treatment onset
  12[^m^](#TN11){ref-type="table-fn"}   Phenobarbital                                                                     Phenobarbital                                   Complete withdrawal                     Nocturia
  13[^f^](#TN10){ref-type="table-fn"}   Lamotrigine + Topiramate                                                          Lamotrigine + Topiramate                        Dosage reduction                        Sleepiness and mild irritation
  14[^m^](#TN11){ref-type="table-fn"}   Oxcarbazepine + Levetiracetam + Topiramate + Valproate semisodium + Risperidone   Topiramate + Risperidone                        Partial withdrawal + dosage reduction   Transient sleepiness and mild irritation when waking up
  15[^m^](#TN11){ref-type="table-fn"}   Risperidone + Oxcarbazepine                                                       Risperidone + Oxcarbazepine                     Dosage reduction                        None

OM, alterations in other prescribed medication after introduction of CE (unaltered: no changes in the use of other medication was made; reduction, reduced the dosage of one or more medication; partial withdrawal, stopped completely the use of one of the medications; withdrawal, stopped completely the use of all other medication with the exception of CE.

female patients;

*male patients*.

At least 60% of patients showed improvements of 20% or more in ADHD, MD, CSID, BD, SD, and SZ. From the 15 patients who presented BD, eight (53.3%) had improvements equal to or above 20% in this symptom category. In AD, only four (26.7%) had improvements equal to or above 20%. The most robust results were found for ADHD, SD, and SZ, with more than 80% of patients presenting improvements equal to or above 30%. The results were particularly impressive for the control of seizures in the five epileptic patients, with seizure reduction of 50% in three cases and 100% in the other two cases. It is also worth noting that CE treatment made it possible to achieve a decrease in the dosage or to discontinue other neuropsychiatric medications in eight out of 10 patients that were receiving OM ([Table 2](#T2){ref-type="table"}).

Untoward Effects
----------------

The following adverse effects were reported among the 15 patients who adhered to CE treatment: sleepiness, moderate irritability (three cases each); diarrhea, increased appetite, conjunctival hyperemia, and increased body temperature (one case each). All these side effects were mild and/or transient. Two patients presented nocturia, which in one case appeared concomitantly to an improvement in sleep quality.

As stated previously, three patients interrupted the treatment before the end of the first month of CE treatment due to adverse effects such as insomnia, irritability, increased heart rate, and worsening of psycho-behavioral crisis. Additionally, there was one patient (Case 2) who adhered to the treatment until the sixth month and, in spite of improvement in some respects, showed significant worsening in psycho-behavioral aspects. The patients who experienced relevant side effects were all receiving several drugs (Patient 1: Clomipramine + Pericyazine; Patient 2: Risperidone + Prometazine + Sodium Valproate; Patient 3: Risperidone + Prometazine), including at least one antipsychotic, and in two cases there was an abrupt cessation of the antipsychotic.

Discussion {#s4}
==========

Here we report an observational study, which collected information provided by the clinician and the patients\' parents during treatment of autistic patients with a CBD-enriched CE containing a rate of \~75:1 CBD to THC. Treatment duration ranged from 6 to 9 months. The initial cohort included 18 patients aged between 7 and 18. Three participants suspended CE use in the first 30 days of treatment, while 15 continued the use of standardized CE for six (01 patient) or nine (14 patients) months. All patients received the equivalent to an average CBD dose of 4.6 mg/kg/day and an average THC dose of 0.06 mg/kg/day. The prescribed THC dose is considered to be substantially below its safety margin ([@B54]). On the other hand, even low doses of pure THC, ranging from 0.04 to 0.12 mg/kg/day, have been previously shown to cause spasticity reduction, increased interest and connection with the environment, increased demonstration of initiative, reduction of seizure frequency, and improvement in dystonia of children with severe epileptic syndromes ([@B82]).

Previous studies have shown reliable efficacy and safety of CE containing a 20:1 CBD to THC proportion for the treatment of syndromes characterized by refractory epilepsy and regressive autism ([@B54]). Our positive results obtained from five epileptic patients ([Table 1](#T1){ref-type="table"} and [Figure 1A](#F1){ref-type="fig"}) corroborate the existing data regarding the effectiveness of CBD-enriched CE in the control of refractory seizures ([@B47]--[@B60]). Moreover, to the best of our knowledge, this is the first report of a marked improvement in autistic symptoms of non-epileptic patients with the use of CE ([Figure 1B](#F1){ref-type="fig"}).

Not all patients benefited equally from the treatment. From the initial cohort of 18 patients, four patients reported negative results. All of these participants were receiving multiple drugs, including at least one antipsychotic, which suggests the occurrence of undesirable drug interactions. In one of these cases, we suspect that the worsening of symptoms may have been due to an abrupt and unsupervised withdrawal of an antipsychotic drug. These observations point to a potential risk of paradoxical effects when introducing CE in a drug combination that includes antipsychotic drugs. This underscores the need for extra vigilance and of a gradual increase in the dosage of EC in patients receiving many drugs, and also to evaluate with caution the possibility of either partial or complete withdrawal of previously prescribed drugs.

Among the 15 patients who adhered to treatment for at least 6 months, 10 were non-epileptic or had not experienced seizures for at least 1 year ([Table 2](#T2){ref-type="table"} and [Figure 1B](#F1){ref-type="fig"}). These patients showed positive effects in almost all evaluated categories, namely: ADHD, MD, AD, CSID, CD, and SD. Particularly among non-epileptic, nine (90%) presented improvement equal to or above 30% in at least one of these categories, six (60%) presented improvement of 30% or more in at least two categories, and four (40%) presented improvement equal to or above 30% in at least four symptom categories ([Table 2](#T2){ref-type="table"}). Therefore, the present observational study corroborates the notion that the range of therapeutic benefits of CBD-enriched CE extends to several distinct autistic symptoms, even in non-epileptic patients.

We note that due to the fact that the behavior/symptoms were annotated by caregivers, results on behavior improvement contain a significant degree of subjectivity. We also note that the reported results are subjectively quantitative, and that the degree of improvement may be non-linear (so that 60% improvement does not necessarily mean twice as much improvement as 30%).

Conspicuous positive effects, in both epileptic and non-epileptic patients, were observed in ADHD, SD, and CSID categories. It is evident that sleep quality improvement and hyperactivity reduction tend to have major positive impacts on mood and general health, as well as on the efficacy of psycho-pedagogic therapeutic interventions. Furthermore, in a long-term perspective, psycho-pedagogic therapy may potentiate the social, cognitive, and behavioral benefits observed after CE treatment. The least pronounced effects were seen on improvement of autonomy deficits (AD). This may indicate a need for a larger time interval to allow for consolidated routines and behavioral patterns, both from patients and from caretakers, to be remodeled before any benefit can be obtained from CE treatment.

The findings presented here, taken together, support the notion that many autism symptoms are associated to neuronal hyperexcitability, and indicate that CBD-enriched CE yields positive effects in multiple autistic symptoms, without causing the typical side effects found in medicated ASD patients. Most patients in this study had improved symptoms even after supervised weaning of other neuropsychiatric drugs. The intrinsic limitations of the present study, due to its observational nature, are the lack of control groups, the small cohort size, and potentially significant placebo effects ([@B83]). Further clinical trials are warranted to confirm these initial findings.
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